The biological role of the Fas/FasL system during tumor formation and progression

被引:117
作者
Reichmann, E [1 ]
机构
[1] Univ Zurich, Childrens Hosp, Dept Pediat Surg, Fetal & Pediat Surg Res Lab, CH-8032 Zurich, Switzerland
关键词
apoptosis; Fas; Fas-ligand; tissue homeostasis; tumor development; anti-cancer therapy;
D O I
10.1016/S1044-579X(02)00017-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The cells of an organism are constantly exposed to conflicting environmental cues that signal cell survival or cell death. Survival signals are delivered by autocrine or paracrine factors that actively suppress a default death pathway. This default death pathway appears to be activated by dedicated death receptors such as Fas, the TRAIL-receptors and other tumor necrosis factor receptor superfamily proteins (TNFR SFPs). Our understanding of how these counteracting receptor systems are modulated during tumorigenesis is only moderate. Nevertheless, there is now broad evidence that susceptibility of tumor cells towards Fas-mediated apoptosis is largely reduced. In addition, tumor cells frequently exhibit de novo expression of Fas-ligand (FasL) which plays a significant role in local tissue destruction, metastatic spread and immune escape of the tumor cells. Restoring the apoptotic potential of cancer cells upon modulating the expression and activity of certain key components of the cell death machinery is an attractive and obvious therapeutic anti-cancer strategy.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 61 条
[1]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[2]   Death receptors: Signaling and modulation [J].
Ashkenazi, A ;
Dixit, VM .
SCIENCE, 1998, 281 (5381) :1305-1308
[3]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[4]   A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling [J].
Chan, FKM ;
Chun, HJ ;
Zheng, LX ;
Siegel, RM ;
Bui, KL ;
Lenardo, MJ .
SCIENCE, 2000, 288 (5475) :2351-2354
[5]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[6]   Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover [J].
French, LE ;
Hahne, M ;
Viard, I ;
Radlgruber, G ;
Zanone, R ;
Becker, K ;
Muller, C ;
Tschopp, J .
JOURNAL OF CELL BIOLOGY, 1996, 133 (02) :335-343
[7]  
Gratas C, 1998, CANCER RES, V58, P2057
[8]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[9]   CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance [J].
Griffith, TS ;
Yu, XH ;
Herndon, JM ;
Green, DR ;
Ferguson, TA .
IMMUNITY, 1996, 5 (01) :7-16
[10]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366